
OBIO Stock Forecast & Price Target
OBIO Analyst Ratings
Bulls say
Orchestra BioMed Holdings Inc. is experiencing an upward trend in research and development (R&D) expenditures, with R&D expenses increasing by 21% year over year to $14.0 million and projected to grow by 36% to $58.2 million in 2025, indicating a strong commitment to innovation and product development. The company's General and Administrative (SG&A) expenses have also risen, reflecting ongoing investments in operational capabilities, with a year-over-year increase of 12% to $26.9 million. The positive outlook is further supported by the strategic focus on risk-reward sharing partnerships with medical device companies, positioning the company to potentially enhance market penetration and sales of its high-impact product candidates, including AVIM Therapy and Virtue SAB.
Bears say
Orchestra BioMed Holdings Inc. has consistently experienced operating losses since its inception, reflecting its challenges as a development-stage company. The ongoing financial deficits indicate that the company may struggle to achieve sustainable profitability in the future. With a persistent track record of losses, there is growing concern about the viability of its business model and the company's ability to generate positive financial outcomes.
This aggregate rating is based on analysts' research of Orchestra BioMed Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
OBIO Analyst Forecast & Price Prediction
Start investing in OBIO
Order type
Buy in
Order amount
Est. shares
0 shares